Boehringer Ingelheim commits to Veeva Vault CRM
Systems announced that Boehringer Ingelheim is the latest global top 20 biopharma company to commit to moving to Veeva Vault CRM.
Boehringer Ingelheim Limited: Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the ...
Mena FN6d
NCLA Asks Second Circuit To Rule Against HHS’S Coercive Medicare Drug Price ‘Negotiation’ Program
(MENAFN- GlobeNewsWire - Nasdaq) Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of health & Human Services, et al. Washington, D.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Today, ...
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
thorax.bmj10d
Associations of pulmonary microvascular blood volume with per cent emphysema and CT emphysema subtypes in the community: the MESA Lung study
Background Pulmonary microvasculature alterations are implicated in emphysema pathogenesis, but the association between ...
WATTAgNet14d
USDA approves use of European avian metapneumovirus vaccine
The National Turkey Federation supports import permit to improve treatment of the contagious respiratory disease.
OpenSecrets.org20d
PAC Profile: Boehringer Ingelheim Corp
You are one of 7.5 million annual visitors to OpenSecrets. If you each donated just $1 a year, we'd never worry about funding again.
emjreviews.com23d
Inhalation Innovation: Phase IIb Study Design of Inhaled Pirfenidone in the Treatment of Progressive Pulmonary Fibrosis
Kolb has received payment from Avalyn Pharma for providing advice for the MIST trial; has received research funding for preclinical work from Boehringer Ingelheim, United Therapeutics, and Structure ...